SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-19-292361
Filing Date
2019-11-14
Accepted
2019-11-14 17:34:14
Documents
2
Group Members
INVOPPS IV US, L.P.INVOPPS IV, L.P.SACHA LAINOVIC

Document Format Files

Seq Description Document Type Size
1 SC 13D d827310dsc13d.htm SC 13D 87550
2 EX-99.1 d827310dex991.htm EX-99.1 5681
  Complete submission text file 0001193125-19-292361.txt   94845
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91186 | Film No.: 191221808
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 126 EAST 56TH STREET, 20THFLOOR NEW YORK NY 10022
Business Address 126 EAST 56TH STREET, 20THFLOOR NEW YORK NY 10022 212-616-2555
InvOpps GP IV, L.L.C. (Filed by) CIK: 0001792570 (see all company filings)

IRS No.: 830954871 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D